The NF-κB signaling cascade has been well studied in IBD treatment and is often dysregulated in patients, resulting in aberrant cytokine and chemokine production in the gut (Zaidi and Wine, 2018; Benary and Wolf, 2019). This evidence concerns the gene NFKB1 and inflammatory bowel disease.